See Shionogi-Sponsored Publications

Publications

Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.

Looking for a specific publication? Use the Search feature above to find content by keyword, author, title, disease state, medicine, or compound. Please note that Search functions site-wide and will take you to a separate results page.

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • Zatolmilast
  • All
  • In vitro
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Real-world evidence
  • Surveillance
  • Review
  • Pharmacokinetics/Pharmaco-dynamics
  • Compatibility
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Fragile X syndrome
  • Gram-negative infection
 
Cefiderocol
Review
Gram-negative infection

Antimicrobial snapshot: cefiderocol

Published:
2026
Authors:
Nguyen ST, Simon S, DeJonge BLM.
View Publication
 
Cefiderocol
Real-world evidence
Gram-negative infection

Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes 

Published:
2026
Authors:
Cantón R, García-Castillo M, Hernández-García M, et al.
View Publication
 
Cefiderocol
In vitro
Gram-negative infection

Evaluation of cefiderocol trailing and other unclear susceptibility testing endpoints for Acinetobacter spp.

Published:
2026
Authors:
Castanheira M, Maher JM, Kimbrough JH, et al
View Publication
 
Cefiderocol
Surveillance
Gram-negative infection

In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024

Published:
2026
Authors:
DeJonge BLM, Longshaw C, Kung F, et al
View Publication
 
Cefiderocol
In vitro
Gram-negative infection

Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa

Published:
2026
Authors:
Yamano Y, Takemura M, Longshaw C, et al.
View Publication